Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

Blood Pressure Assessment in Atrial Fibrillation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2014 by University of Athens.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
George S. Stergiou, University of Athens
ClinicalTrials.gov Identifier:
NCT01088269
First received: March 16, 2010
Last updated: August 15, 2014
Last verified: August 2014
History of Changes

March 16, 2010
August 15, 2014
March 2010
December 2014   (final data collection date for primary outcome measure)
Blood Pressure Measurement in Atrial Fibrillation,Serum Markers and echocardiographic indexes in atrial fibrillation (AF) [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  1. Evaluation of the oscillometric technique of an electronic device in blood pressure measurement.
  2. Evaluation of the relationship of blood pressure levels with serum markers and ultrasonographic cardiac indexes.
  3. Evaluation of a 24h ambulatory blood pressure monitoring device (Microlife WatchBPO3) in terms of its diagnostic value for the detection of atrial fibrillation compared with the reference 24h Holter ECG
Blood Pressure Measurement in Atrial Fibrillation,Serum Markers and echocardiographic indexes in AF [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  1. Evaluation of the oscillometric technique of an electronic device in blood pressure measurement.
  2. Evaluation of the relationship of blood pressure levels with serum markers and ultrasonographic cardiac indexes.
Complete list of historical versions of study NCT01088269 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Blood Pressure Assessment in Atrial Fibrillation
Evaluation of the Oscillometric Blood Pressure Measurement in Atrial Fibrillation and Relation of Blood Pressure With Serum Biomarkers and Echocardiographic Indexes

This is a cross-sectional study including patients with permanent atrial fibrillation. Assessment will include:

  • clinic blood pressure measurements (mercury sphygmomanometer and automated oscillometric device)
  • 24-hour ambulatory blood pressure monitoring
  • determination of various serum markers and cardiac ultrasound.
  • evaluation of a 24h ambulatory blood pressure monitoring device (Microlife WatchBPO3) in terms of its diagnostic value for the detection of atrial fibrillation compared with the reference 24h Holter ECG
Not Provided
Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample
SUBJECTS REFERRED TO HYPERTENSION CENTER
Atrial Fibrillation
Not Provided
  • AF
    Hypertensive patients in AF
  • Non-AF
    Hypertensive Patients
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
February 2015
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Hypertensives adults in atrial fibrillation

Exclusion Criteria:

  • Renal disease (Cr > 2 mg/l).
  • Patients with pacemaker rhythm during the study.
  • Each patient with acute disease (inflammation, surgery), malignancy, collagen diseases, pulmonary fibrosis, renal failure, liver failure, chronic inflammatory diseases.
Both
25 Years to 85 Years   (Adult, Senior)
No
Contact: George S Stergiou, MD +302107763117 gstergi@med.uoa.gr
Greece
 
NCT01088269
BPM IN AF
No
Not Provided
Not Provided
George S. Stergiou, University of Athens
University of Athens
Not Provided
Study Chair: George S Stergiou, MD Hypertension Center,Third Department of Medicine,University of Athens,Greece
University of Athens
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP